RESUMO
Background: The current study aimed to investigate the efficacy of the Ischemia Reversal program (IRP) as an Ayurveda based therapy to standard anti-ischemic therapy in patients with ischemic heart disease (IHD). Methods: A retrospective, single centre, observational study was conducted from January 2022 to May 2023. A total of 39 patients diagnosed with ischemic heart disease and global longitudinal strain (GLS) <15, regardless of underlying co-morbidities such as diabetes mellitus, hypertension, obesity, hyperlipidemia, low ejection fraction, history of myocardial infarction were included in this study. The primary endpoint was improvement in GLS from baseline to the 90-day follow-up in various different categories. Secondary endpoints were improvement in EF, abdominal girth, weight and reduction in dependency on allopathic medication from baseline to the 90-day follow-up. Results: The mean age of the study population was 59.23±9.01 years. Weight (day 1: 67.29±13.16 kg and day 90: 61.39±11.11 kg; p=0.00), body mass index (day 1: 25.75±4.03 and day 90: 23.79±3.50; p=0.00), abdominal girth (day 1: 95.31±10.75 cm and day 90: 85.67±17.02 cm p=0.00), EF (day 1: 40.74±10.30% and day 90: 53.91±11.87%; p=0.00), and GLS (day 1: -10.99±2.72 and day 90: -13.17±3.75; p=0.00) improved at the 90 day follow-up. Conclusions: The study showed notable improvements in weight, body mass index, abdominal girth, EF, and GLS after 90 days. These results suggest that IRP is beneficial treatment for IHD, but more extensive research is needed to confirm its effectiveness.
RESUMO
Background: Diabetes mellitus, in particular, has emerged as a significant health concern, affecting millions of individuals and placing a considerable strain on the healthcare system. Promoting remission of diabetes, wherein patients achieve a state of sustained blood sugar control without the need for ongoing medication or with a reduced reliance on medication, can yield remarkable benefits. This study sought to understand the role of Aahar and Panchakarma on restoration of euglycemia in known type 2 diabetes patients. Methods: A retrospective, observational, cohort study was conducted at Madhavbaug Cardiac Care Clinic between April 2021 and April 2022 in Maharashtra, India. Patients aged 18 years and older with a diagnosis of type 2 diabetes mellitus with glycated haemoglobin level (HbA1c) >7% and had participated in the Comprehensive Diabetes Care (CDC) program were included in this study. Parameters such as HbA1c, body weight, body mass index (BMI), and dependence on conventional allopathic medication were assessed at the end of the CDC program. Follow-up was conducted at 90 days. Day 1 and day 90 data were compared. Results: Of the 45 patients, 17 (40.5%) patients had a negative glucose tolerance and 14 (33.3%) patients had impaired glucose tolerance. HbA1c, body weight, and BMI improved at the end of CDC program. Dependency on conventional allopathic medications was also reduced. Conclusions: Restoration of euglycemia in patients with type 2 diabetes mellitus is possible, however, further studies to understand the affecting factors are warranted.